To achieve the objective of eliminating malaria in Guatemala, timely access to appropriate treatment is a key strategy for the Ministry of Health. One of the mainstays of this strategy is the network of community volunteers who provide diagnosis and treatment for malaria in their communities. After an assessment identifying weaknesses in the management of … Read more
Improving Medicines Access and Use for Child Health—A Guide to Developing Interventions represents an up-to-date[i] and practical resource for those developing interventions to improve access to and use of medicines for child illness. While it primarily targets groups working in community organizations, health facilities, and district health offices, it could also be used within the … Read more
SIAPS Program presentations from the 2016 Global Health Mini-University are now available at the links below. For additional presentation materials and photos from the March 4 event, click here. SIAPS Presentations Introducing New TB Medicines and Regimens: Is Success Driven By Systems? Building Systems for Access and Appropriate Use of iCCM Medicines Increasing Access to … Read more
For the first time in the Democratic Republic of the Congo (DRC), 13 life-saving health commodities for mothers and children have been included in the National Health Development Plan (NHDP). These medicines are recommended by the United Nations Commission on Life-Saving Commodities for Women and Children (UNCoLSC). The move by the Ministry of Public Health … Read more
In 2012, bedaquiline was conditionally approved by the U.S. Food and Drug Administration for the treatment of drug-resistant tuberculosis (TB), making it the first new TB drug to enter the market in more than 40 years. With the rise of multidrug-resistant and extensively drug-resistant TB leaving patients with fewer treatment options, the approval of bedaquiline … Read more
The WHO End TB Strategy aims to end the global TB epidemic with a three-pronged approach. Targets include reducing TB deaths by 95%, cutting new cases by 90% between 2015 and 2035, and ensuring that no family is burdened with catastrophic expenses due to TB. Our new infographic shows how SIAPS is fighting TB in line with … Read more
In April 2015, USAID and Janssen Therapeutics officially launched the bedaquiline (BDQ) donation initiative, under which Janssen committed to providing free BDQ to 30,000 patients with multidrug-resistant tuberculosis (MDR-TB) over a four-year period. Along with delamanid, BDQ is one of only two new TB medicines released to the market in over 40 years. These medicines … Read more
In April 2015, USAID and Janssen Therapeutics officially launched the bedaquiline (BDQ) donation initiative, under which Janssen committed to providing free BDQ to 30,000 patients with multidrug-resistant tuberculosis (MDR-TB) over a four-year period. Along with delamanid, BDQ is one of only two new TB medicines released to the market in over 40 years. These medicines … Read more
In April 2015, USAID and Janssen Therapeutics officially launched the bedaquiline (BDQ) donation initiative, under which Janssen committed to providing free BDQ to 30,000 patients with multidrug-resistant tuberculosis (MDR-TB) over a four-year period. Along with delamanid, BDQ is one of only two new TB medicines released to the market in over 40 years. These medicines … Read more
In Swaziland, the USAID-funded SIAPS Program has taken great strides in ensuring country ownership and sustainability of local technical assistance initiatives. Since 2012, SIAPS has supported quantification efforts in Swaziland, providing extensive support to the Ministry of Health (MoH) in conducting quantification exercises for antiretrovirals (ARVs), TB medicines, and sexual and reproductive health commodities to … Read more
